secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001701541-25-000038
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Q3 net loss $8.5M, cash $135.5M; silevertinib Phase 2 ORR data due Q4 2025
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments $135.5M as of Sept 30, 2025; funds operations into Q4 2027.
- Net loss $8.5M in Q3 2025 vs $15.6M in Q3 2024; R&D expenses fell to $7.4M from $12.9M.
- ORR and preliminary duration of treatment data from silevertinib Phase 2 in 1L non-classical EGFRm NSCLC expected later this quarter.
- PFS data from Phase 2 trial expected in H1 2026; company plans FDA feedback on registrational path.
- Exploring partnership opportunities for silevertinib in NSCLC and glioblastoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154125000038/0001701541-25-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154125000038/bdtx-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001701541-25-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer